Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis

Hamon, David; Algalarrondo, Vincent; Gandjbakhch, Estelle; Extramiana, Fabrice; Marijon, Éloi; Elbaz, Nathalie; Selhane, D.; Dubois‐Randé, Jean‐Luc; Teiger, Emmanuel; Planté‐Bordeneuve, Violaine; Damy, Thibaud; Lellouche, Nicolas

doi:10.1016/j.ijcard.2016.07.254

Cited by 82 publications

(70 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A few small retrospective studies to date have investigated the incidence and outcomes of appropriate cardioverter‐defibrillator therapy in patients with cardiac amyloidosis. Hamon et al studied 45 patients with CA who underwent ICD implantation, of whom 60% had ATTR CA. Of these 45 patients, 27% had at least one appropriate ICD therapy.…”

Section: Discussionmentioning

confidence: 99%

Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality

Donnellan

Wazni

Saliba

et al. 2019

Cardiovasc electrophysiol

View full text Add to dashboard Cite

Background The aim of our study was to investigate outcomes of patients with ATTR (amyloidosis and transthyretin) CA (cardiac amyloidosis) and implantable devices with respect to left ventricular ejection fraction (LVEF), mitral regurgitation (MR), New York Heart Association (NYHA) functional class, and mortality. Methods This was a retrospective observational cohort study of 78 patients with ATTR CA and implantable devices. During a mean follow‐up of 42 months we investigated the impact of right ventricular (RV) pacing burden and biventricular (BiV) pacing on LVEF, MR severity, NYHA functional class, and mortality. Results Worsening MR occurred in 11% of patients with a RV pacing % <40% compared to 62% of those with a RV pacing burden >40% (P = .002). Similarly, worsening LVEF occurred in 26% of patients who were RV paced <40% and 89% of those who were RV paced >40% of the time (P < .0001) and worsening in NYHA functional class occurred in 22% and 89%, respectively (P < .0001). Improvement in LVEF, NYHA functional class, and MR severity occurred in 78%, 67%, and 67%, respectively, in those with BiV devices. Death occurred in 67% of patients in the cardiac resynchronization therapy group compared to 68% of those with a RV pacing burden <40% and 92% of those with a RV pacing burden >40%. Conclusion A higher RV pacing burden is associated with deleterious remodeling and congestive heart failure in patients with ATTR CA, whereas BiV pacing is associated with improvements in LVEF, NYHA class, and degree of MR. BiV pacing should be considered in patients with ATTR CA and an indication for pacing. However, further larger prospective studies will need to be performed.

show abstract

Section: Discussionmentioning

confidence: 99%

Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality

Donnellan

Wazni

Saliba

et al. 2019

Cardiovasc electrophysiol

View full text Add to dashboard Cite

show abstract

“…4 Despite this, improvement in overall survival has not been clearly demonstrated. 5,6 One reason for this is the difficulty in identifying patients who would benefit. 7 In addition, electromechanical dissociation is responsible for a significant portion of death and it is not amendable to ICD.…”

mentioning

confidence: 99%

DSMA Renal Scan in Cardiac Amyloidosis

Leung

2019

Mayo Clinic Proceedings

View full text Add to dashboard Cite

“…По данным некоторых регистров, частота оправданных срабатываний ИКД достигает при амилоидозе (в основном TTR) 27% менее чем за 5 месяцев [26]. Интересно, что в 84% случаев про-филактика была первичной, показанием к ней были постановка в лист ожидания на трансплантацию, предположительно аритмогенные обмороки, ФВ <35% и частая желудочковая эктопия с потребно-стью в стимуляции.…”

Section: Discussionunclassified

Clinical Masks of Amyloidosis With the Heart Involvement: Modern Diagnostic Issues

Недоступ¹,

Седов²,

Kogan³

et al. 2017

Russ J Cardiol

View full text Add to dashboard Cite

Outcome and incidence of appropriate implantable cardioverter-defibrillator therapy in patients with cardiac amyloidosis

Cited by 82 publications

References 28 publications

Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality

Cardiac devices in patients with transthyretin amyloidosis: Impact on functional class, left ventricular function, mitral regurgitation, and mortality

DSMA Renal Scan in Cardiac Amyloidosis

Clinical Masks of Amyloidosis With the Heart Involvement: Modern Diagnostic Issues

Contact Info

Product

Resources

About